FdaApplication
NDA 208276
Identifiers
- fda_app_no: NDA208276
Properties
| Property | Value |
|---|---|
| applicant_name | UNITED THERAPEUTICS CORP |
| application_type | NDA |
| approval_date | 2018-07-30 |
Revenue by product
REMODULIN
| Period | Revenue |
|---|---|
| Q2 2026 | $126.3M |
| Q1 2026 | $126.6M |
| Q4 2025 | $128.0M |
| Q3 2025 | $125.9M |
| Q2 2025 | $134.7M |
| Q1 2025 | $138.2M |
| Q4 2024 | $134.5M |
| Q3 2024 | $128.3M |
| Q2 2024 | $147.3M |
| Q1 2024 | $128.0M |
| Q4 2023 | $115.1M |
| Q3 2023 | $131.1M |
| Q2 2023 | $127.2M |
| Q1 2023 | $121.4M |
| Q4 2022 | $122.5M |
| Q3 2022 | $114.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REMODULIN | TREPROSTINIL | 100MG/20ML (5MG/ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS |
| REMODULIN | TREPROSTINIL | 20MG/20ML (1MG/ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS |
| REMODULIN | TREPROSTINIL | 200MG/20ML (10MG/ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS |
| REMODULIN | TREPROSTINIL | 50MG/20ML (2.5MG/ML) | SOLUTION;INTRAVENOUS, SUBCUTANEOUS |
4 products